Tracon Pharmaceuticals Inc (TCON) - News Archive

In a shocking turn of events, TRACON Pharmaceuticals announced the termination of its employees and the winding down of its operations. This decision was reached at a special meeting of the board of directors, sending s...

In a recent announcement, TRACON Pharmaceuticals revealed the termination of its ENVASARC trial due to unsatisfactory results. This decision has prompted the company to explore strategic alternatives while harnessing it...

Tracon Pharmaceuticals Inc, a San Diego-based company specializing in biological products, has experienced a lackluster performance compared to the overall market. This article aims to provide an analysis of the company...

Promising New Data on TRC102 in Recurrent Glioblastoma: Enhancing Temodar Efficacy TRACON Pharmaceuticals, Inc. (NASDAQ: TCON) has announced encouraging findings published in the peer-reviewed journal Clinical Cancer Re...

TRACON Pharmaceuticals Implements Reverse Stock Split to Strengthen Position in Biopharmaceutical MarketIn the fast-paced and competitive world of biopharmaceuticals, companies must constantly adapt and evolve to meet t...

In recent updates, TRACON Pharmaceuticals has provided positive news regarding its ongoing ENVASARC pivotal Phase 2 trial. The company disclosed a significant increase in the Objective Response Rate (ORR) by investigato...